Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Guiling Li

Showing results (191-200 of 227) with videos related to

Pageof 23
Sort By:
Nature Communications|July 13, 2016
Golgi membrane fission requires the CtBP1-S/BARS-induced activation of lysophosphatidic acid acyltransferase δAlessandro Pagliuso, Carmen Valente, Lucia Laura Giordano, et al.
Plos One|March 8, 2013
Decreased dicer expression enhances SRP-mediated protein targetingYong-Feng Ren, Guiling Li, Yong-Feng Xue, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|February 16, 2021
Solid Tumor Complicated With Venous Thromboembolism: A 10-Year Retrospective Cross-Sectional StudyMiao Peng, Shengli Yang, Guiling Li, et al.
Frontiers in Immunology|May 8, 2023
Efficacy and safety of serplulimab plus nab-paclitaxel in previously treated patients with PD-L1-positive advanced cervical cancer: a phase II, single-arm studyJusheng An, Xiumin Li, Jing Wang, et al.
Carcinogenesis|August 7, 2013
Hepatitis B surface antigen inhibits MICA and MICB expression via induction of cellular miRNAs in hepatocellular carcinoma cellsJianmin Wu, Xue-Jiao Zhang, Ke-Qing Shi, et al.
BMJ Open|May 25, 2022
Sintilimab combined with bevacizumab in relapsed/persistent ovarian clear cell carcinoma (INOVA): an investigator-initiated, multicentre clinical trial-a study protocol of clinical trialRuyuan Li, Xingyu Liu, Chunyan Song, et al.
BMC Medicine|September 29, 2023
A phase 1 trial of fuzuloparib in combination with apatinib for advanced ovarian and triple-negative breast cancer: efficacy, safety, pharmacokinetics and germline BRCA mutation analysisYaxin Liu, Wei Wang, Rutie Yin, et al.
Bone Research|November 14, 2022
Correction To: Fetuin-A is an immunomodulator and a potential therapeutic option in BMP4-dependent heterotopic ossification and associated bone mass lossChen Kan, Jiazhao Yang, Haitao Fan, et al.
Bone Research|October 26, 2022
Fetuin-A is an immunomodulator and a potential therapeutic option in BMP4-dependent heterotopic ossification and associated bone mass lossChen Kan, Jiazhao Yang, Haitao Fan, et al.
Targeted Oncology|January 13, 2025
Fruquintinib Plus Sintilimab in Patients with Treatment-Naive and Previously Treated Advanced Renal Cell Carcinoma: Results from a Phase Ib/II Clinical TrialHua Xu, Xin Yao, Zhisong He, et al.
Pageof 23

Showing results (191-200 of 227) with videos related to

Sort By:
Pageof 23
Nature Communications|July 13, 2016
Golgi membrane fission requires the CtBP1-S/BARS-induced activation of lysophosphatidic acid acyltransferase δAlessandro Pagliuso, Carmen Valente, Lucia Laura Giordano, et al.
Plos One|March 8, 2013
Decreased dicer expression enhances SRP-mediated protein targetingYong-Feng Ren, Guiling Li, Yong-Feng Xue, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|February 16, 2021
Solid Tumor Complicated With Venous Thromboembolism: A 10-Year Retrospective Cross-Sectional StudyMiao Peng, Shengli Yang, Guiling Li, et al.
Frontiers in Immunology|May 8, 2023
Efficacy and safety of serplulimab plus nab-paclitaxel in previously treated patients with PD-L1-positive advanced cervical cancer: a phase II, single-arm studyJusheng An, Xiumin Li, Jing Wang, et al.
Carcinogenesis|August 7, 2013
Hepatitis B surface antigen inhibits MICA and MICB expression via induction of cellular miRNAs in hepatocellular carcinoma cellsJianmin Wu, Xue-Jiao Zhang, Ke-Qing Shi, et al.
BMJ Open|May 25, 2022
Sintilimab combined with bevacizumab in relapsed/persistent ovarian clear cell carcinoma (INOVA): an investigator-initiated, multicentre clinical trial-a study protocol of clinical trialRuyuan Li, Xingyu Liu, Chunyan Song, et al.
BMC Medicine|September 29, 2023
A phase 1 trial of fuzuloparib in combination with apatinib for advanced ovarian and triple-negative breast cancer: efficacy, safety, pharmacokinetics and germline BRCA mutation analysisYaxin Liu, Wei Wang, Rutie Yin, et al.
Bone Research|November 14, 2022
Correction To: Fetuin-A is an immunomodulator and a potential therapeutic option in BMP4-dependent heterotopic ossification and associated bone mass lossChen Kan, Jiazhao Yang, Haitao Fan, et al.
Bone Research|October 26, 2022
Fetuin-A is an immunomodulator and a potential therapeutic option in BMP4-dependent heterotopic ossification and associated bone mass lossChen Kan, Jiazhao Yang, Haitao Fan, et al.
Targeted Oncology|January 13, 2025
Fruquintinib Plus Sintilimab in Patients with Treatment-Naive and Previously Treated Advanced Renal Cell Carcinoma: Results from a Phase Ib/II Clinical TrialHua Xu, Xin Yao, Zhisong He, et al.
Pageof 23